Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes
1 other identifier
interventional
180
1 country
1
Brief Summary
This prospective study aimed to validate a new prognostic approach of endothelial progenitor cells associated biomarkers in patients with acute coronary syndromes . Recruitment is made prospectively by two centers of Inter -region South Mediterranean,
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2014
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 15, 2014
CompletedFirst Posted
Study publicly available on registry
April 17, 2014
CompletedStudy Start
First participant enrolled
June 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2018
CompletedMay 8, 2026
August 1, 2018
3.2 years
April 15, 2014
May 4, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
evaluate the value of circulating endothelial progenitor cells quantification in the initial phase of ACS in predicting the occurrence of a major cardiovascular event (ECVM ) at 1 year.
one year
Secondary Outcomes (1)
determine the technical characteristics (sensitivity and specificity) and predictive value of the number of PEC
one day , one month , one year
Other Outcomes (2)
determine the technical characteristics (sensitivity and specificity) and performance (technical and predictive) of chemokines / receptors expression in the occurrence of ECVM
one day, one month ,one year
Determine the above performance in the subgroup of patients defined as incompletely revascularized (at least a residual stenosis < 70%)
one year
Study Arms (1)
study of PEC markers and chemokines/ chemokine recep
OTHERblood sample for dosage and study of PEC markers and chemokines/ chemokine receptors
Interventions
Eligibility Criteria
You may qualify if:
- acute coronary syndrome (ST + \< 12 hours and ST- high risk or intermediate risk ),which there is an indication of percutaneous coronary intervention.
You may not qualify if:
- Cancer
- Chronic inflammatory disease
- Infectious disease
- Erythrocyte \<4 G/l
- Thrombopénia less than 100 000/mm3 ;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
assistance Publique Hopitaux de Marseille
Marseille, 13015, France
Related Publications (1)
Buelens C, De Groote D, Goldman M, Willems F. Differential effects of interleukin-10 on the production of interleukin-12 and interleukin-8 by human dendritic cells generated from peripheral blood. Transplant Proc. 1996 Dec;28(6):3255-6. No abstract available.
PMID: 8962261RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 15, 2014
First Posted
April 17, 2014
Study Start
June 1, 2014
Primary Completion
August 1, 2017
Study Completion
August 1, 2018
Last Updated
May 8, 2026
Record last verified: 2018-08